Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

• Publication date: February 2012

Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017 Summary Leading business intelligence provider GBI Research has released its latest research report, “Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017”, which provides insight about immunomodulators sales forecasts until 2...

Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

Summary

Leading business intelligence provider GBI Research has released its latest research report, “Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017”, which provides insight about immunomodulators sales forecasts until 2017.I Immunomodulators markets in the key geographies of the US, Europe and other relevant regions are also covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classes, which include immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, and antimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). The report also explores the competitive landscape, with a competitive analysis of the top companies in the market.

GBI Research analysis estimated the global immunomodulators market to be valued at $145.9 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 13.1% between 2002 and 2010. The market is forecast to grow at a CAGR of 8.6% between 2010 and 2017, to reach $259.3 billion in 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and in–house analysis by the GBI Research team of experts.

GBI Research analysis found the R&D pipeline for the immunomodulators market to be strong. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that R&D activity for immunomodulators will remain active for at least next four to five years.

Scope

- Data and analysis of the immunomodulators market in the leading geographies of the US and Europe. Different drug classes of immunomodulators discussed in the report are immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, antimetabolites) and immunostimulants (antibodies, interferon alpha and vaccines).
- Annualized market data for the immunomodulators market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
- Key drivers and restraints that have had significant impact on the market.
- Competitive landscape of the global immunomodulators market including benchmarking of the top companies. The key companies studied in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Bristol-Myers Squibb, Eli Lilly.

Reasons to buy

- Build effective strategies to launch pipeline products, by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of the top competitors.
- Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first–in-class molecules with improved efficacy and safety profiles.

Global Biological Therapy Industry

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 13
2 Immunomodulators Market to 2017 - Market Introduction 17
2.1 GBI Research Report Guidance 17
3 Immunomodulators Market to 2017 - Market Characterization 19
3.1 Classification 19
3.2 Drivers and Barriers 20
3.3 Global Immunomodulators Market Drivers 20
3.4 Global Immunomodulators Market Restraints 21
3.5 Unmet Needs 22
3.6 Revenue Forecast - Global 23
4 Immunomodulators Market to 2017 - Geographical Landscape 27
4.1 The US 27
4.2 Europe 28
4.3 ROW 29
5 Immunomodulators Market to 2017 - Immunosuppressants 30
5.1 Introduction 30
5.2 Drug Classes 30
5.3 Applications 30
5.4 Global Market Size 31
6 Immunosuppressants - Antibodies 32
6.1 Introduction 32
6.2 Prescription Population 33
6.3 Annual Cost of Therapy 37
6.4 Revenue 42
6.5 Pipeline Molecules 46
7 Immunosuppressants - Interferon Beta 50
7.1 Introduction 50
7.2 Prescription Population 50
7.3 Annual Cost of Therapy 55
7.4 Revenue 59
7.5 Pipeline Molecules 63
8 Immunosuppressants - Glucocorticoids 65
8.1 Introduction 65
8.2 Therapeutic Indications 65
8.3 Immunological Mode of Action 65
8.4 Prescription Population 67
8.5 Annual Cost of Therapy 71
8.6 Revenue 75
8.7 Pipeline Molecules 79
9 Immunosuppressants - Calcineurin Inhibitors 104
9.1 Introduction 104
9.2 Prescription Population 104
9.3 Annual Cost of Therapy 109
9.4 Revenue 113
9.5 Pipeline Molecules 117
10 Immunosuppressants - Antimetabolites 137
10.1 Introduction 137
10.2 Prescription Population 137
10.3 Annual Cost of Therapy 142
10.4 Revenue 146
10.5 Pipeline Molecules 150
11 Immunomodulators Market to 2017 - Immunostimulants 189
11.1 Introduction 189
11.2 Drug Classes 189
11.3 Applications 189
11.4 Global Market Size 190
12 Immunostimulants - Vaccines, Active Immunity 191
12.1 Introduction 191
12.2 Target Population 192
12.3 Revenue 193
12.4 Pipeline Molecules 198
13 Immunostimulants: Antibodies - Passive Immunity 210
13.1 Introduction 210
13.2 Prescription Population 210
13.3 Annual Cost of Therapy 215
13.4 Revenue 219
13.5 Pipeline Molecules 223
14 Immunostimulants: Interferon Alpha - Passive Immunity 235
14.1 Introduction 235
14.2 Prescription Population 236
14.3 Annual Cost of Therapy 240
14.4 Revenue 244
14.5 Pipeline Molecules 248
15 Immunomodulators Market to 2017 - Competitive Landscape 257
15.1 Market Share Analysis 257
15.2 Hoffmann-La Roche Ltd Roche 258
15.3 Amgen Inc 259
15.4 Abbott Laboratories 260
15.5 Johnson & Johnson 261
15.6 Novartis AG 262
15.7 Biogen Idec 264
15.8 Merck & Co Inc 265
15.9 Bristol Myers Squibb Company 266
15.10 Eli Lilly and Company 267
16 Immunomodulators Market to 2017 - Strategic Consolidations 269
16.1 M&A Deals by Type 269
16.2 M&A Landscape 270
16.3 Major Deals 272
16.4 Licensing Deals 273
16.5 Major Deals 275
16.6 Partnership Deals 276
16.7 Major Deals 279
17 Immunomodulators Market to 2017 - Appendix 280
17.1 Market Definitions 280
17.2 Abbreviations 280
17.3 Research Methodology 281
17.4 Therapeutic Landscape 282
17.5 Geographical Landscape 285
17.6 Pipeline Analysis 285
17.7 Competitive Landscape 285
17.8 Contact Us 285
17.9 Disclaimer 285
17.10 Sources 286

1.1 List of Tables

Table 1: Immunomodulators Market to 2017, Global, Revenue ($bn), 2002-2010 27
Table 2: Immunomodulators Market to 2017, Global, Revenue Forecasts ($bn), 2010-2017 27
Table 3: Immunomodulators Market to 2017, Global, Annual Cost of Therapy ($), 2002-2010 29
Table 4: Immunomodulators Market to 2017, Global, Annual Cost of Therapy ($), 2010-2017 29
Table 5: Immunomodulators Market to 2017, Global, Prescription Population (million), 2002-2010 30
Table 6: Immunomodulators Market to 2017, Global, Prescription Population (million), 2010-2017 30
Table 7: Immunomodulators Market to 2017, The US, Revenue ($bn), 2002-2010 31
Table 8: Immunomodulators Market to 2017, The US, Revenue Forecasts (bn), 2010-2017 31
Table 9: Immunomodulators Market to 2017, Europe, Revenue ($bn), 2002-2010 32
Table 10: Immunomodulators Market to 2017, Europe, Revenue Forecasts ($bn), 2010-2017 32
Table 11: Immunomodulators Market to 2017, ROW, Revenue ($bn), 2002-2010 33
Table 12: Immunomodulators Market to 2017, ROW, Revenue Forecasts ($bn), 2010-2017 33
Table 13: Immunomodulators Market to 2017, Immunosuppressants, Global, Revenue ($bn), 2002-2010 35
Table 14: Immunomodulators Market to 2017, Immunosuppressants, Global, Revenue Forecasts ($bn), 2010-2017 35
Table 15: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Prescription Population (million), 2002-2010 37
Table 16: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Prescription Population (million), 2010-2017 37
Table 17: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Prescription Population (million), 2002-2010 38
Table 18: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Prescription Population (million), 2010-2017 38
Table 19: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Prescription Population (million), 2002-2010 39
Table 20: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Prescription Population (million), 2010-2017 39
Table 21: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Prescription Population (million), 2002-2010 40
Table 22: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Prescription Population (million), 2010-2017 40
Table 23: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2010 41
Table 24: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Annual Cost of Therapy ($), 2010-2017 42
Table 25: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2010 42
Table 26: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Annual Cost of Therapy ($), 2010-2017 43
Table 27: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2010 44
Table 28: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Annual Cost of Therapy ($), 2010-2017 44
Table 29: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2010 45
Table 30: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Annual Cost of Therapy ($), 2010-2017 45
Table 31: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue ($bn), 2002-2010 46
Table 32: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue Forecasts ($bn), 2010-2017 46
Table 33: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Revenue ($bn), 2002-2010 47
Table 34: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Revenue Forecasts ($bn), 2010-2017 48
Table 35: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Revenue ($bn), 2002-2010 48
Table 36: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Revenue Forecasts ($bn), 2010-2017 49
Table 37: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Revenue ($bn), 2002-2010 49
Table 38: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Revenue Forecasts ($bn), 2010-2017 50
Table 39: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase III, 2011 50
Table 40: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase II, 2011 51
Table 41: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase I, 2011 52
Table 42: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Preclinical/Discovery Phase, 2011 52
Table 43: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Prescription Population (million), 2002-2010 55
Table 44: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Prescription Population (million), 2010-2017 55
Table 45: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Prescription Population, 2002-2010 56
Table 46: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Prescription Population, 2010-2017 56
Table 47: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Prescription Population, 2002-2010 57
Table 48: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Prescription Population, 2010-2017 57
Table 49: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Prescription Population, 2002-2010 58
Table 50: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Prescription Population, 2010-2017 58
Table 51: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Annual Cost of Therapy ($), 2002-2010 59
Table 52: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Annual Cost of Therapy ($), 2010-2017 59
Table 53: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US Annual Cost of Therapy ($), 2002-2010 60
Table 54: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US Annual Cost of Therapy ($), 2010-2017 60
Table 55: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Annual Cost of Therapy ($), 2002-2010 61
Table 56: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Annual Cost of Therapy ($), 2010-2017 61
Table 57: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Annual Cost of Therapy ($), 2002-2010 62
Table 58: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Annual Cost of Therapy ($), 2010-2017 62
Table 59: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Revenue ($bn), 2002-2010 63
Table 60: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Revenue Forecasts ($bn), 2010-2017 63
Table 61: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Revenue ($bn), 2002-2010 64
Table 62: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Revenue Forecasts ($bn), 2010-2017 64
Table 63: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Revenue ($bn), 2002-2010 65
Table 64: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Revenue Forecasts ($bn), 2010-2017 65
Table 65: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Revenue ($bn), 2002-2010 66
Table 66: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Revenue Forecasts ($bn), 2010-2017 66
Table 67: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase III, 2011 67
Table 68: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase II, 2011 67
Table 69: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase I, 2011 67
Table 70: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Preclinical/Discovery Phase, 2011 68
Table 71: Immunomodulators Market to 2017, Comparative Glucocorticoid Potency, 2011 70
Table 72: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Prescription Population (million), 2002-2010 71
Table 73: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Prescription Population (million), 2010-2017 71
Table 74: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Prescription Population (million), 2002-2010 72
Table 75: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Prescription Population (million), 2010-2017 73
Table 76: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Prescription Population (million), 2002-2010 73
Table 77: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Prescription Population (million), 2010-2017 74
Table 78: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Prescription Population (million), 2002-2010 74
Table 79: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Prescription Population (million), 2010-2017 75
Table 80: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Annual Cost of Therapy ($), 2002-2010 75
Table 81: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Annual Cost of Therapy ($), 2010-2017 76
Table 82: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Annual Cost of Therapy ($), 2002-2010 76
Table 83: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Annual Cost of Therapy ($), 2010-2017 76
Table 84: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Annual Cost of Therapy ($), 2002-2010 77
Table 85: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Annual Cost of Therapy ($), 2010-2017 77
Table 86: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Annual Cost of Therapy ($), 2002-2010 78
Table 87: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Annual Cost of Therapy ($), 2010-2017 78
Table 88: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Revenue ($bn), 2002-2010 79
Table 89: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Revenue Forecasts ($bn), 2010-2017 79
Table 90: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Revenue ($bn), 2002-2010 80
Table 91: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Revenue Forecasts ($bn), 2010-2017 81
Table 92: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Revenue ($bn), 2002-2010 81
Table 93: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Revenue Forecasts ($bn), 2010-2017 81
Table 94: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Revenue ($bn), 2002-2010 82
Table 95: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Revenue Forecasts ($bn), 2010-2017 82
Table 96: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase III, 2011 83
Table 97: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase II, 2011 90
Table 98: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase I, 2011 106
Table 99: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Preclinical/Discovery Phase, 2011 107
Table 100: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Prescription Population, 2002-2010 109
Table 101: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Prescription Population, 2010-2017 109
Table 102: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Prescription Population, 2002-2010 110
Table 103: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Prescription Population, 2010-2017 110
Table 104: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Prescription Population, 2002-2010 111
Table 105: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Prescription Population, 2010-2017 111
Table 106: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Prescription Population, 2002-2010 112
Table 107: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Prescription Population, 2010-2017 112
Table 108: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Annual Cost of Therapy ($), 2002-2010 113
Table 109: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Annual Cost of Therapy ($), 2010-2017 113
Table 110: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Annual Cost of Therapy ($), 2002-2010 114
Table 111: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Annual Cost of Therapy ($), 2010-2017 114
Table 112: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Annual Cost of Therapy ($), 2002-2010 115
Table 113: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Annual Cost of Therapy ($), 2010-2017 115
Table 114: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Annual Cost of Therapy ($), 2002-2010 116
Table 115: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Annual Cost of Therapy ($), 2010-2017 116
Table 116: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Revenue ($bn), 2002-2010 117
Table 117: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Revenue Forecasts ($bn), 2010-2017 117
Table 118: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Revenue ($bn), 2002-2010 118
Table 119: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Revenue Forecasts ($bn), 2010-2017 118
Table 120: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Revenue ($bn), 2002-2010 119
Table 121: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Revenue Forecasts ($bn), 2010-2017 119
Table 122: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Revenue ($bn), 2002-2010 120
Table 123: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Revenue Forecasts ($bn), 2010-2017 120
Table 124: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase III, 2011 121
Table 125: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase II, 2011 122
Table 126: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase I, 2011 137
Table 127: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Preclinical/Discovery Phase, 2011 140
Table 128: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Prescription Population (million), 2002-2010 142
Table 129: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Prescription Population (million), 2010-2017 142
Table 130: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Prescription Population (million), 2002-2010 143
Table 131: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Prescription Population (million), 2010-2017 143
Table 132: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Prescription Population (million), 2002-2010 144
Table 133: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Prescription Population (million), 2010-2017 144
Table 134: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Prescription Population (million), 2002-2010 145
Table 135: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Prescription Population (million), 2010-2017 145
Table 136: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Annual Cost of Therapy ($), 2002-2010 146
Table 137: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Annual Cost of Therapy ($), 2010-2017 146
Table 138: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Annual Cost of Therapy ($), 2002-2010 147
Table 139: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Annual Cost of Therapy ($), 2010-2017 147
Table 140: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Annual Cost of Therapy ($), 2002-2010 148
Table 141: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Annual Cost of Therapy ($), 2010-2017 148
Table 142: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Annual Cost of Therapy ($), 2002-2010 149
Table 143: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Annual Cost of Therapy ($), 2010-2017 149
Table 144: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Revenue ($bn), 2002-2010 150
Table 145: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Revenue Forecasts ($bn), 2010-2017 150
Table 146: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Revenue ($bn), 2002-2010 151
Table 147: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Revenue Forecasts ($bn), 2010-2017 151
Table 148: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Revenue ($bn), 2002-2010 152
Table 149: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Revenue Forecasts ($bn), 2010-2017 152
Table 150: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Revenue ($bn), 2002-2010 153
Table 151: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Revenue Forecasts ($bn), 2010-2017 153
Table 152: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase III, 2011 154
Table 153: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase II, 2011 160
Table 154: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase I, 2011 179
Table 155: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Preclinical/Discovery Phase, 2011 187
Table 156: Immunomodulators Market to 2017, Immunostimulants, Revenue ($bn), 2002-2010 194
Table 157: Immunomodulators Market to 2017, Immunostimulants, Revenue Forecasts ($bn), 2010-2017 194
Table 158: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Vaccine Preventable Disease, 2010 195
Table 159: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Target Pediatric and Adult Population (‘000), 2002-2010 196
Table 160: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Target Pediatric and Adult Population (‘000), 2010-2017 197
Table 161: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Revenue ($bn), 2002-2010 198
Table 162: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Revenue Forecasts ($bn), 2010-2017 198
Table 163: Immunomodulators Market to 2017, Immunostimulants, Vaccines, The US, Revenue ($bn), 2002-2010 199
Table 164: Immunomodulators Market to 2017, Immunostimulants, Vaccines, The US, Revenue Forecasts ($bn), 2010-2017 199
Table 165: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Europe, Revenue ($bn), 2002-2010 200
Table 166: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Europe, Revenue Forecasts ($bn), 2010-2017 200
Table 167: Immunomodulators Market to 2017, Immunostimulants, Vaccines, ROW, Revenue ($bn), 2002-2010 202
Table 168: Immunomodulators Market to 2017, Immunostimulants, Vaccines, ROW, Revenue Forecasts ($bn), 2010-2017 202
Table 169: Immunomodulators Market to 2017, Immunostimulants, Vaccines, NDA Filed Molecules, 2011 202
Table 170: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase III, 2011 203
Table 171: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase II, 2011 206
Table 172: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase I, 2011 209
Table 173: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Preclinical/Discovery Phase, 2011 210
Table 174: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Prescription Population (million), 2002-2010 215
Table 175: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Prescription Population (million), 2010-2017 215
Table 176: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Prescription Population (million), 2002-2010 216
Table 177: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Prescription Population (million), 2010-2017 216
Table 178: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Prescription Population (million), 2002-2010 217
Table 179: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Prescription Population (million), 2010-2017 217
Table 180: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Prescription Population (million), 2002-2010 218
Table 181: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Prescription Population (million), 2010-2017 218
Table 182: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2010 219
Table 183: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Annual Cost of Therapy ($), 2010-2017 219
Table 184: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2010 220
Table 185: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Annual Cost of Therapy ($), 2010-2017 220
Table 186: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2010 221
Table 187: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Annual Cost of Therapy ($), 2010-2017 221
Table 188: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2010 222
Table 189: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Annual Cost of Therapy ($), 2010-2017 222
Table 190: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Revenue ($bn), 2002-2010 223
Table 191: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Revenue Forecasts ($bn), 2010-2017 223
Table 192: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Revenue ($bn), 2002-2010 224
Table 193: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Revenue Forecasts ($bn), 2010-2017 225
Table 194: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Revenue ($bn), 2002-2010 225
Table 195: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Revenue Forecasts ($bn), 2010-2017 225
Table 196: Immunomodulators Market to 2017, Immunostimulants, I Antibodies, ROW, Revenue ($bn), 2002-2010 226
Table 197: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Revenue Forecasts ($bn), 2010-2017 226
Table 198: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, NDA Filed, 2011 227
Table 199: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase III, 2011 227
Table 200: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase II, 2011 229
Table 201: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase I, 2011 235
Table 202: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Preclinical/Discovery Phase, 2011 237
Table 203: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Pharmaceutical Forms of Interferons, 2011 239
Table 204: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Prescription Population, 2002-2010 240
Table 205: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Prescription Population, 2010-2017 240
Table 206: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Prescription Population, 2002-2010 241
Table 207: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Prescription Population, 2010-2017 242
Table 208: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Prescription Population, 2002-2010 242
Table 209: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Prescription Population, 2010-2017 243
Table 210: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue ($bn), 2002-2010 243
Table 211: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($bn), 2010-2017 244
Table 212: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Annual Cost of Therapy ($), 2002-2010 244
Table 213: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Annual Cost of Therapy ($), 2010-2017 245
Table 214: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Annual Cost of Therapy ($), 2002-2010 245
Table 215: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Annual Cost of Therapy ($), 2010-2017 246
Table 216: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Annual Cost of Therapy ($), 2002-2010 246
Table 217: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Annual Cost of Therapy ($), 2010-2017 247
Table 218: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Annual Cost of Therapy ($), 2002-2010 247
Table 219: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Annual Cost of Therapy ($), 2010-2017 248
Table 220: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Revenue ($bn), 2002-2010 248
Table 221: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Revenue Forecasts ($bn), 2010-2017 249
Table 222: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Revenue ($bn), 2002-2010 249
Table 223: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Revenue Forecasts ($bn), 2010-2017 249
Table 224: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Revenue ($bn), 2002-2010 250
Table 225: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Revenue Forecasts ($bn), 2010-2017 250
Table 226: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue ($m), 2002-2010 251
Table 227: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($m), 2010-2017 251
Table 228: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase III, 2011 252
Table 229: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase II, 2011 254
Table 230: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase I, 2011 259
Table 231: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Preclinical/Discovery Phase, 2011 260
Table 232: Immunomodulators Market to 2017, Roche, Marketed Products, Sales ($m), 2010 262
Table 233: Immunomodulators Market to 2017, Amgen Inc, Marketed Products, Sales ($m), 2010 263
Table 234: Immunomodulators Market to 2017, Abbott Laboratories, Marketed Products, Sales ($m), 2010 264
Table 235: Immunomodulators Market to 2017, Johnson & Johnson, Marketed Products, Sales ($m), 2010 265
Table 236: Immunomodulators Market to 2017, Novartis AG, Marketed Products, Sales ($m) 2010 267
Table 237: Immunomodulators Market to 2017, Biogen Idec, Marketed Products, Sales ($m), 2010 268
Table 238: Immunomodulators Market to 2017, Merck & Co Inc, Marketed Products, Sales ($m), 2010 269
Table 239: Immunomodulators Market to 2017, Bristol-Myers Squibb Company, Marketed Products, Sales ($m), 2010 270
Table 240: Immunomodulators Market to 2017, Eli Lilly and Company, Marketed Products, Sales ($m), 2010 271
Table 241: Immunomodulators Market to 2017, Global, Strategic Consolidations, M&A by Year, 2010-2011 274
Table 242: Immunomodulators Market to 2017, Global, Strategic Consolidations, Top Five M&A Deals by Value, 2010-2011 276
Table 243: Immunomodulators Market to 2017, Global, St